InMed Pharmaceuticals (INM) Company Report

InMed Pharmaceuticals Inc. held its 2025 Annual General and Special Meeting on December 17, 2025, with 35.43% of the Company's issued and outstanding common shares represented.
Shareholders approved the election of five director nominees to the board, with "Votes For" percentages ranging from 81.94% to 82.11%.
CBIZ CPAs P.C. was approved as the Company's auditors for the following year with 78.84% of votes for.
Shareholders also approved the potential issuance of 20% or more of the Company's common shares pursuant to the Standby Equity Purchase Agreement (SEPA), with 65.89% of votes for.

Dec 18, 2025, 4:55 PM

8-K

InMed Pharmaceuticals Inc. reports potential negative impact on BayMedica commercial business

INM

Profit Warning

New Projects/Investments

InMed Pharmaceuticals Inc. announced that H.R. 5371, the "Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026," which was recently signed into law, is expected to have a material negative impact on its subsidiary, BayMedica Inc..
If the Act comes into force on November 12, 2026, in its current form, it would prohibit certain aspects of BayMedica's commercial business and its inventory of rare, non-intoxicating cannabinoids.
BayMedica is currently evaluating alternative supply chain options to maintain continued regulatory compliance.
InMed's core pharmaceutical drug development programs, including INM-901 for Alzheimer's disease and INM-089 for age-related macular degeneration (AMD), are not affected by this new legislation and continue to progress.

Dec 15, 2025, 2:32 PM

8-K

InMed Pharmaceuticals Provides Update on Drug Development Pipeline and Financials

INM

New Projects/Investments

Guidance Update

InMed Pharmaceuticals (INM) is advancing a pipeline of proprietary small molecule drug candidates, including INM-901 for Alzheimer's disease and INM-089 for dry age-related macular degeneration, both currently in preclinical stages.
The company's INM-755 cannabinol cream, which completed Phase 2 clinical trials for epidermolysis bullosa and demonstrated a clinically meaningful improvement in chronic itch in 66% of patients, is actively seeking a strategic partner for Phase 3 development.
As of September 30th, InMed Pharmaceuticals reported a cash balance of $9.3 million, providing an estimated one year's runway, and maintains a clean balance sheet with no debt.
Future key value drivers include progressing INM-901 and INM-089 towards IND filings and securing strategic partnerships for its programs, with a current prioritization on INM-901 due to its potential impact on Alzheimer's.

Dec 11, 2025, 7:00 PM

Transcript

InMed Pharmaceuticals Presents Drug Development Pipeline and Financial Update

INM

New Projects/Investments

Guidance Update

InMed Pharmaceuticals (NASDAQ: INM) is a drug development company focused on proprietary small molecule drug candidates for Alzheimer's (INM-901), ocular disease (INM-089 for dry AMD), and dermatology (INM-755).
As of September 30th, the company reported $9.3 million in the bank, providing an estimated one year's runway, with 4.2 million shares outstanding and a market capitalization of approximately $5.6 million.
INM-755, a cannabinol cream for epidermolysis bullosa, completed Phase 2 trials, demonstrating a clinically meaningful improvement in chronic itch in 66% of patients, and InMed is actively seeking a partner for Phase 3 development.
The company is prioritizing the advancement of INM-901 for Alzheimer's disease, which is in preclinical development and has shown a statistically significant reduction in neuroinflammation and improvement in behavior and cognitive functions in animal studies.

Dec 11, 2025, 7:00 PM

Transcript

InMed Pharmaceuticals provides update on drug pipeline and financial position

INM

New Projects/Investments

Guidance Update

InMed Pharmaceuticals is a drug development company focused on proprietary small molecule drug candidates, with INM-901 for Alzheimer's (preclinical), INM-089 for dry AMD (preclinical), and INM-755 for chronic itch (completed Phase 2 clinical trials).
As of September 30th, the company reported $9.3 million in cash, providing an estimated one-year runway, and has a clean balance sheet with no debt.
Key priorities include advancing INM-901 and INM-089 towards IND filings and identifying strategic partners for its drug development programs.

Dec 11, 2025, 7:00 PM

Transcript

InMed Pharmaceuticals Announces Successful Completion of Pharmacokinetic Studies for Alzheimer's Candidate INM-901

INM

New Projects/Investments

InMed Pharmaceuticals Inc. announced on November 18, 2025, the successful completion of pharmacokinetic (PK) studies in large animal models for its Alzheimer’s disease candidate, INM-901.
The studies demonstrated a favorable bioavailability profile for the INM-901 oral formulation, achieving anticipated therapeutic levels of systemic exposure.
Neurological assessments revealed no adverse neural or behavioral effects, reinforcing the compound’s favorable safety profile.
These results will support the design and planning of first-in-human clinical trials, and the company is preparing for a pre-Investigational New Drug (IND) meeting with the FDA.

Nov 19, 2025, 9:28 PM

8-K

InMed Pharmaceuticals Reports FY2025 Financial Results and Business Update

INM

Earnings

Guidance Update

New Projects/Investments

InMed Pharmaceuticals Inc. reported a net loss of $8.2 million for the fiscal year ended June 30, 2025, an increase from $7.7 million in the prior year.
The company held $11.1 million in cash, cash equivalents, and short-term investments as of June 30, 2025, which is projected to fund operations into the fourth quarter of calendar year 2026.
The BayMedica commercial segment recorded $4.9 million in sales for fiscal year 2025, representing an 8% increase compared to the previous year.
Significant progress was made in the INM-901 program for Alzheimer's disease, with preclinical studies showing reduced neuroinflammation and improved cognitive function, and plans to advance towards an IND submission in fiscal 2026.

Sep 23, 2025, 9:24 PM

8-K

InMed Pharmaceuticals Provides Update on Drug Pipeline and Financial Position

INM

New Projects/Investments

Guidance Update

InMed Pharmaceuticals is advancing its drug pipeline, with INM-901 for Alzheimer's and INM-089 for dry age-related macular degeneration both in preclinical phases and planning pre-IND meetings with the FDA next year.
Preclinical data for INM-901 demonstrated reduced amyloid beta load, neuroinflammation, increased neuroprotection, and improved cognitive functions in a mouse model.
The company is seeking partnerships for INM-755, a CBN cream that completed a Phase 2 study for epidermolysis bullosa, showing strong anti-itch activity, to advance it to Phase 3.
InMed's commercial entity, BayMedica, generates approximately $5 million per year from manufacturing rare cannabinoids for the health and wellness market and is profitable.
The company reported an estimated cash balance of $9.2 million at the end of June, providing a cash runway into the fourth quarter of calendar 2026.